Genmab announces bispecific antibody research deal with Kyowa Hakko

The companies are also considering signing a licensing contract to develop new DuoBody product.

Genmab’s DuoBody platform swiftly generates bispecific antibodies through a process performed at standard bench, in addition to commercial, manufacturing scale.

DuoBody molecules that feature bispecificity can be administered and dosed as other antibody therapeutics.

Genmab chief executive officer Jan van de Winkel said, "We believe this keen level of interest on the part of top tier pharmaceutical companies clearly illustrates the promise of bispecific antibodies created with the DuoBody platform, and also demonstrates the technology’s compatibility with a range of antibody-platforms"

The financial terms of the transaction, which is not expected to show an impact on Genmab’s 2012 financial guidance, were not revealed.